New promising drug targets in cancer- and mtastasis-initiating cells

Murielle Mimeault, Surinder Kumar Batra

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.

Original languageEnglish (US)
Pages (from-to)354-364
Number of pages11
JournalDrug Discovery Today
Volume15
Issue number9-10
DOIs
StatePublished - Jan 1 2010

Fingerprint

Pharmaceutical Preparations
Neoplasms
Neoplasm Metastasis
DNA Repair Enzymes
Recurrence
Therapeutics
Growth

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

New promising drug targets in cancer- and mtastasis-initiating cells. / Mimeault, Murielle; Batra, Surinder Kumar.

In: Drug Discovery Today, Vol. 15, No. 9-10, 01.01.2010, p. 354-364.

Research output: Contribution to journalReview article

@article{4820adcd2f374cb8908b4b7e155a4f1b,
title = "New promising drug targets in cancer- and mtastasis-initiating cells",
abstract = "The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.",
author = "Murielle Mimeault and Batra, {Surinder Kumar}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.drudis.2010.03.009",
language = "English (US)",
volume = "15",
pages = "354--364",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "9-10",

}

TY - JOUR

T1 - New promising drug targets in cancer- and mtastasis-initiating cells

AU - Mimeault, Murielle

AU - Batra, Surinder Kumar

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.

AB - The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.

UR - http://www.scopus.com/inward/record.url?scp=77950853025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950853025&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2010.03.009

DO - 10.1016/j.drudis.2010.03.009

M3 - Review article

VL - 15

SP - 354

EP - 364

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 9-10

ER -